EP1720524A2 - Comprimes a liberation prolongee de clarithromycine - Google Patents

Comprimes a liberation prolongee de clarithromycine

Info

Publication number
EP1720524A2
EP1720524A2 EP05708615A EP05708615A EP1720524A2 EP 1720524 A2 EP1720524 A2 EP 1720524A2 EP 05708615 A EP05708615 A EP 05708615A EP 05708615 A EP05708615 A EP 05708615A EP 1720524 A2 EP1720524 A2 EP 1720524A2
Authority
EP
European Patent Office
Prior art keywords
extended release
pharmaceutically acceptable
clarithromycin
tablets
release tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05708615A
Other languages
German (de)
English (en)
Inventor
Prashant Manohar Mandaogade
Rajeev Singh Raghuvanshi
Ashok Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN306DE2004 external-priority patent/IN2004DE00306A/en
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1720524A2 publication Critical patent/EP1720524A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to extended release tablets for oral administration comprising clarithromycin and a pharmaceutically acceptable carrier, and processes for their preparation.
  • Background of the Invention Oral ingestion is one of the primary routes used for drug administration. This route provides a convenient method of effectively achieving both local and systemic effects. In conventional oral drug delivery systems there is little or no control over the release of the drug and an effective concentration can only be maintained by repeated administrations. Controlled release systems provide a uniform concentration of drug at the absorption site for an extended period of time and thus, after absorption, allow maintenance of plasma concentrations within a desired therapeutic range. This reduces the frequency of administration. The advantages of controlled release dosage forms for extended or sustained action are well known.
  • the macrolide antibiotics are known for their anti-bacterial activity against a number of micro-organisms and are typically administered as immediate release (IR) compositions two or three times a day for about 10 to 14 days.
  • IR immediate release
  • Clarithromycin (6-O-methylerythromycin A), in particular, has a very bitter metallic taste which can result in poor compliance of the dosing regimen or selection of another therapeutic agent, possibly making it a less effective therapeutic agent.
  • An approach to address the possible non-compliance with the regimen is to develop controlled release solid preparations containing erythromycin derivatives.
  • an extended release tablet of clarithromycin for oral administration includes clarithromycin and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier includes a mixture of lactose and microcrystalline cellulose in a ratio ranging from 3:1 to 1:3.
  • Embodiments of the pharmaceutical composition may include one or more of the following features.
  • the clarithromycin may be between about 50% to about 75% w/w of the total tablet weight and the pharmaceutically acceptable carrier may be present from about 20% to about 30% w/w of the total tablet weight.
  • the lactose includes one or more of anhydrous lactose, spray-dried lactose and lactose monohydrate.
  • the extended release tablet may further include one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients.
  • the rate-controlling polymers may be one or more of carbohydrate gums, polyuronic acid salts, cellulose ethers, acrylic acid polymers and mixtures thereof.
  • the carbohydrate gums may be one or more of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan and locust bean gum.
  • the polyuronic acid salts may be one or more of sodium alginate, potassium alginate and ammonium alginate.
  • the cellulose ethers may be one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose and hydroxyethyl cellulose.
  • the acrylic polymer may be one or both of polyacrylic polymer and carboxy vinyl polymer.
  • the rate controlling polymers may be present from about 0.1% to about 4.5% w/w of total tablet weight.
  • the pharmaceutically acceptable excipients may be one or more of binders, lubricants, glidants, colorants and flavoring agents.
  • the binders may be one or more of starch, sugars, gums, low molecular weight hydroxypropyl methylcellulose, polyvinyl pyrrolidone and hydroxypropyl cellulose.
  • the lubricants may be one or more of talc, magnesium stearate, calcium stearate, polyethylene glycol, hydrogenated vegetable oils, stearic acid, sodium stearyl fumarate and sodium benzoate.
  • the glidants may be one or both of colloidal silicon dioxide and talc.
  • the extended release tablet may further include one or more of omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol and ritonavir.
  • a process for the preparation of extended release tablets of clarithromycin for oral administration includes blending clarithromycin, a pharmaceutically acceptable carrier, one or more rate- controlling polymers and one or more binders to form a blend; screening the blend; lubricating the blend; compressing the blend to form tablets; and optionally coating the tablets.
  • the pharmaceutically acceptable carrier comprises a mixture of lactose and microcrystalline cellulose in a ratio ranging from 3:1 to 1 :3.
  • the process includes blending clarithromycin, a pharmaceutically acceptable carrier, one or more rate-controlling polymers and one or more binders to form a blend; compacting the blend to form granules; sizing the granules; lubricating the granules; compressing to form tablets; and optionally coating the tablets.
  • the pharmaceutically acceptable carrier comprises a mixture of lactose and microcrystalline cellulose in a ratio ranging from 3:1 to 1 :3.
  • Embodiments of the process may include one or more of the following features.
  • the granulation technique used may be wet or dry granulation.
  • a method of treatment for bacterial infections in a mammal in need of treatment includes administering an extended release tablet of clarithromycin that includes clarithromycin and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier includes a mixture of lactose and microcrystalline cellulose in a ratio ranging from 3:1 to 1:3.
  • the extend release tablet may further include one or more of omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol and ritonavir.
  • the inventors have surprisingly now formulated extended release tablets of clarithromycin.
  • the tablets include clarithromycin, one or more rate-controlling polymers and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier includes a mixture of lactose and microcrystalline cellulose in a ratio ranging from about 3:1 to about 1:3.
  • Various ratios of lactose and microcrystalline cellulose may be employed for preparing tablets, such as about 1.5 to about 1, about 2.3 to about 1, about 3 to about 1 and about 1 to about 3. Tablets containing only lactose were also prepared and it was found that these tablets exhibited significantly higher C ma x (peak plasma concentration).
  • Solid dosage forms the most commonly used method of drug delivery, have seen an increasing sophistication in terms of functionality of the excipients.
  • excipients from inert ingredients to functional components has occurred. It is recognized that excipients are critical for stability, safety and performance of the dosage forms.
  • Suitable lactose includes one or more of anhydrous lactose, spray-dried lactose and lactose monohydrate. For example, lactose monohydrate may be used.
  • Microcrystalline cellulose revolutionized tabletting because of its unique compressibility and carrying capacity.
  • microcrystalline cellulose particularly valuable as a filler and binder for formulations prepared by direct compression, although it is also used in wet or dry granulation. It is commercially available under the tradename EMCOCELTM from Edward Mendell Co., Inc. and as AvicelTM from FMC Corp.
  • the pharmaceutically acceptable carrier which includes lactose and microcrystalline cellulose, may be present at from about 20% to about 30% w/w of the total tablet weight.
  • Suitable rate-controlling polymers of the extended release tablets include one or more of carbohydrate gum, polyuronic acid salts, cellulose ethers, acrylic acid polymers and mixtures, thereof.
  • Suitable carbohydrate gums include one or more of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan, locust bean gum and other carbohydrate gums having similar properties.
  • Suitable polyuronic acid salts include one or more of alkali metal salts of alginic acid or pectic acid and mixtures thereof.
  • Suitable alkali metal salts of alginic acid that may be used include one or more of sodium alginate, potassium alginate, ammonium alginate and other suitable alkali metal salts of alginic acid.
  • Suitable cellulose ethers include one or more of hydroxypropyl methyl cellulose, hydroxypropyl cellulose and other suitable cellulose ethers.
  • Suitable acrylic acid polymers include any suitable polyacrylic acid polymers or carboxyvinyl polymers such as those available under the brand name carbopol. The one or more rate-controlling polymers may be present at a concentration from about 0.1% to about 4.5%w/w of the total tablet weight.
  • the extended release tablets may additionally contain one or more pharmaceutically acceptable excipients including one or more of binders, lubricants, glidants, colorants and flavoring agents.
  • Suitable binders include one or more of starch, sugars, gums, low molecular weight hydroxypropyl methylcellulose, polyvinyl pyrrolidone, polyethylene glycols, polyvinyl acetate and hydroxypropyl cellulose.
  • Suitable lubricants include one or more of talc, magnesium stearate, calcium stearate, polyethylene glycol, hydrogenated vegetable oils, stearic acid, sodium stearyl fumarate and sodium benzoate.
  • Suitable glidants include colloidal silicon dioxide (aerosil) or talc.
  • Suitable coloring or flavoring agents include those approved for use by the United
  • the pharmaceutically acceptable carrier includes a mixture of lactose and microcrystalline cellulose in a ratio ranging from about 3:1 to about 1 :3.
  • the tablets may be prepared by direct compression.
  • the clarithromycin may be blended with one or more rate-controlling polymers and a pharmaceutically acceptable carrier which includes a mixture of lactose and microcrystalline cellulose and one or more pharmaceutically acceptable excipients. This blend is screened and compressed after lubrication.
  • the tablets may also be prepared by wet granulation or dry granulation.
  • the clarithromycin may be blended with one or more rate-controlling polymers and a pharmaceutically acceptable carrier which includes a mixture of lactose and microcrystalline cellulose and one or more pharmaceutically acceptable excipients. This blend is then granulated with a suitable binder solution to obtain granules. The granules are further lubricated and compressed.
  • the process of preparing the extended release tablets of clarithromycin includes blending clarithromycin, a pharmaceutically acceptable carrier, which includes lactose and microcrystalline cellulose in a ratio ranging from 3:1 to 1 :3, one or more rate-controlling polymers and one or more binders; screening the blend; lubricating the blend; compressing the blend to form tablets; and optionally coating the tablets.
  • the process of preparing the extended release tablets of clarithromycin includes blending clarithromycin, a pharmaceutically acceptable carrier, which includes lactose and microcrystalline cellulose in a ratio ranging from 3:1 to 1:3 and one or more rate-controlling polymers; compacting the blend, screening into granules; lubricating the granules; compressing to form tablets; and optionally coating the tablets.
  • a pharmaceutically acceptable carrier which includes lactose and microcrystalline cellulose in a ratio ranging from 3:1 to 1:3 and one or more rate-controlling polymers
  • the process of preparing the extended release tablets of clarithromycin includes blending clarithromycin, a pharmaceutically acceptable carrier, which includes lactose and microcrystalline cellulose in a ratio ranging from 3:1 to 1:3 and one or more rate-controlling polymers; granulating the blend with a solution of binder; drying the granules, screening the granules, lubricating the granules; compressing the granules to form tablets; and optionally coating the tablets. Also provided is a method of treating a bacterial infection.
  • the method includes administering extended release tablets of clarithromycin which include clarithromycin and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier includes a mixture of lactose and microcrystalline cellulose in a ratio ranging from 3 : 1 to 1:3.
  • the method of treating may further include concurrently administering one or more of omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir with clarithromycin.
  • Clarithromycin, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, microcrystalline cellulose and lactose were sieved through a British Standard Sieve (BSS) 18 mesh sieve, blended together and granulated with binder solution. The resulting granulate was dried in a fluid bed drier. The dried granules were sized and lubricated with the remaining ingredients and compressed to form tablets. The tablets were coated with opadry dispersion.
  • BSS British Standard Sieve
  • clarithromycin ER tablets (formulated as per Examples 3 and 4) are suitable for administration to a patient for extended release. Similar studies were carried out in which 500 mg clarithromycin ER tablets were prepared according to Example 5. Values for the pharmacokinetic parameters, including observed C max , AUC 0 - t and AUCQ.CC, were calculated using standard non-compartmental methods. The results are indicated by the ratio of test to reference are shown in Table 2. Table 2: Summary of pharmacokinetic parameters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des comprimés à libération prolongée destinés à une administration par voie orale, qui comprennent de la clarithromycine et un excipient pharmaceutiquement acceptable, ainsi que des procédés permettant de les préparer.
EP05708615A 2004-02-26 2005-02-25 Comprimes a liberation prolongee de clarithromycine Withdrawn EP1720524A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN306DE2004 IN2004DE00306A (fr) 2001-08-22 2004-02-26
PCT/IB2005/000502 WO2005082331A2 (fr) 2004-02-26 2005-02-25 Comprimes a liberation prolongee de clarithromycine

Publications (1)

Publication Number Publication Date
EP1720524A2 true EP1720524A2 (fr) 2006-11-15

Family

ID=34897732

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05708615A Withdrawn EP1720524A2 (fr) 2004-02-26 2005-02-25 Comprimes a liberation prolongee de clarithromycine

Country Status (2)

Country Link
EP (1) EP1720524A2 (fr)
WO (1) WO2005082331A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803450A1 (fr) 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Compositions pharmaceutiques pour éradiquer helicobacter pylori
CN100438917C (zh) * 2006-07-20 2008-12-03 山东聊城阿华制药有限公司 一种微晶纤维素乳糖的制备方法
WO2008114143A1 (fr) * 2007-03-22 2008-09-25 Aurobindo Pharma Limited Formulations à libération prolongée d'un antibiotique macrolide
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
EP2671571A1 (fr) * 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations à libération contrôlée de clarithromycine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6610328B2 (en) * 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6663891B2 (en) * 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
KR100508992B1 (ko) * 2003-03-31 2005-08-17 한국유나이티드제약 주식회사 쓴 맛을 개선한 클래리스로마이신 경구용 약제 조성물 및 그의 제조 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005082331A2 *

Also Published As

Publication number Publication date
WO2005082331A3 (fr) 2006-03-30
WO2005082331A2 (fr) 2005-09-09

Similar Documents

Publication Publication Date Title
US20200000726A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
EP1432408B1 (fr) Compositions pharmaceutiques a base de dioxyde de silicium colloidal
CA2675724A1 (fr) Composition orale a liberation prolongee
CN106943355B (zh) 药物组合物
US10525009B2 (en) Formulations of 6-mercaptopurine
US20020081332A1 (en) Controlled release formulation of erythromycin or a derivative thereof
KR101017862B1 (ko) 네비라핀의 서방성 제형
AU2005232582A1 (en) Imroved formulations of 6-mercaptopurine
US7943585B2 (en) Extended release antibiotic composition
EP1720524A2 (fr) Comprimes a liberation prolongee de clarithromycine
WO2005102289A1 (fr) Formulation a liberation prolongee de clarithromycine
EP2593081B1 (fr) Composition de comprimé à base de ferrimannitol-ovalbumine
JPWO2013147135A1 (ja) 放出制御医薬組成物
RU2603469C2 (ru) Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления
KR20180035723A (ko) 라코사미드 서방성 제제
WO2024028262A1 (fr) Nouvelle formulation
WO2021009605A1 (fr) Comprimés dispersibles d'acétate d'abiratérone
AU2010200758A1 (en) Pharmaceutical compositions comprising colloidal silicon dioxide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061002

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17Q First examination report despatched

Effective date: 20080220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080701